Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.

Molecular and cellular endocrinology - 5 Sept 2013

Mologni Luca, Redaelli Sara, Morandi Andrea, Plaza-Menacho Ivan, Gambacorti-Passerini Carlo

Abstract excerpt

RET kinase is aberrantly activated in thyroid cancers and in rare cases of lung and colon cancer, and has been validated as a molecular target in these tumors. Vandetanib was recently approved for the treatment of medullary thyroid cancer. However, vandetanib is ineffective in vitro against RET mutants carrying bulky aminoacids at position 804, the gatekeeper residue, similarly to drug-resistant BCR-ABL mutants...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to HEK293 Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imidazoles

Share to Inhibitory Concentration 50

Share to Mutant Proteins

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-ret

Share to Pyridazines

Source

Identifiers

PMID: 23811235
DOI: 10.1016/j.mce.2013.06.025

Genes

RET
BCR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.PMID 23811235Read ↗

RET fusions observed in lung and colorectal cancers are sensitive to ponatinibSemantic proximity Read ↗

State-of-the-Art Strategies for Targeting RET -Dependent CancersSemantic proximity Read ↗

RET kinase inhibitors for the treatment of RET-altered thyroid cancers: Current knowledge and future directions.Semantic proximity Read ↗

Resistance to RET-Inhibition in RET-Rearranged NSCLC Is Mediated By Reactivation of RAS/MAPK Signaling.Semantic proximity Read ↗

Targeting RET alterations in cancer: Recent progress and future directions.Semantic proximity Read ↗

Discovery of CN-3 as a Next-Generation RET Inhibitor Potently Overcoming Multiple Mutations.Semantic proximity Read ↗

Systematic Analysis of Tyrosine Kinase Inhibitor Response to RET Gatekeeper Mutations in Thyroid Cancer.Semantic proximity Read ↗

Targeting RET Receptor Tyrosine Kinase Activation in CancerSemantic proximity Read ↗

Selective RET kinase inhibition for patients with RET-altered cancers.Semantic proximity Read ↗

RET kinase inhibitors: a review of recent patents (2012–2015)Semantic proximity Read ↗

Drug resistance profiles of mutations in the RET kinase domain.Semantic proximity Read ↗

RET Signaling Pathway in Human Cancer: Oncogenic Mechanisms, Selective Inhibitors, and Emerging Resistance Strategies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.